{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:51:59Z","timestamp":1791373919405,"version":"4.3.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00120-026-02886-5","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:21:14Z","timestamp":1783588874000},"page":"1050-1057","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Geriatrische Assessments und ihre praktische Anwendung in der Uroonkologie","Geriatric assessments and their practical application in uro-oncology"],"prefix":"10.1007","volume":"65","author":[{"given":"Christian","family":"Fiebig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Manseck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Piotrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fr\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Umbehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Butea-Bocu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wiedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"2886_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262311314","author":"A Smirnov","year":"2025","unstructured":"Smirnov\u00a0A, Semionov\u00a0M, Yasinski\u00a0V et\u00a0al (2025) Post-Operative Delirium in Elderly Patients: A Narrative Review. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms262311314","journal-title":"Int J Mol Sci"},{"key":"2886_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136071","volume":"10","author":"JW Raats","year":"2015","unstructured":"Raats\u00a0JW, van Eijsden\u00a0WA, Crolla\u00a0RM et\u00a0al (2015) Risk Factors and Outcomes for Postoperative Delirium after Major Surgery in Elderly Patients. PLoS One 10:e0136071. https:\/\/doi.org\/10.1371\/journal.pone.0136071","journal-title":"PLoS One"},{"key":"2886_CR3","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1001\/jamaoncol.2023.0998","volume":"9","author":"MK Nowakowska","year":"2023","unstructured":"Nowakowska\u00a0MK, Ortega\u00a0RM, Wehner\u00a0MR et\u00a0al (2023) Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol 9:930\u2013937. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0998","journal-title":"JAMA Oncol"},{"key":"2886_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/nu10050555","author":"V Malafarina","year":"2018","unstructured":"Malafarina\u00a0V, Reginster\u00a0JY, Cabrerizo\u00a0S et\u00a0al (2018) Nutritional Status and Nutritional Treatment Are Related to Outcomes and Mortality in Older Adults with Hip Fracture. Nutrients. https:\/\/doi.org\/10.3390\/nu10050555","journal-title":"Nutrients"},{"key":"2886_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/0003-4819-152-6-201003160-00008","volume":"152","author":"P Haentjens","year":"2010","unstructured":"Haentjens\u00a0P, Magaziner\u00a0J, Colon-Emeric\u00a0CS et\u00a0al (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380\u2013390. https:\/\/doi.org\/10.7326\/0003-4819-152-6-201003160-00008","journal-title":"Ann Intern Med"},{"key":"2886_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14238603","author":"Y Ito","year":"2025","unstructured":"Ito\u00a0Y, Yamamoto\u00a0N, Tomita\u00a0Y et\u00a0al (2025) Time to Death and Nursing Home Admission in Older Adults with Hip Fracture: A Retrospective Cohort Study. J\u00a0Clin Med. https:\/\/doi.org\/10.3390\/jcm14238603","journal-title":"J Clin Med"},{"key":"2886_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2025.102773","volume":"16","author":"C Martin","year":"2025","unstructured":"Martin\u00a0C, Banks\u00a0J, Battisti\u00a0NML et\u00a0al (2025) Treatment decision-making and quality of life versus length of life preferences of older patients with early stage cancer: A systematic review. J\u00a0Geriatr Oncol 16:102773. https:\/\/doi.org\/10.1016\/j.jgo.2025.102773","journal-title":"J Geriatr Oncol"},{"key":"2886_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","volume":"116","author":"HJ Boyle","year":"2019","unstructured":"Boyle\u00a0HJ, Alibhai\u00a0S, Decoster\u00a0L et\u00a0al (2019) Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer 116:116\u2013136. https:\/\/doi.org\/10.1016\/j.ejca.2019.04.031","journal-title":"Eur J Cancer"},{"key":"2886_CR9","isbn-type":"print","volume-title":"Guidelines. Edn. presented at the EAU Annual Congress London 2026","author":"EAU","year":"2026","unstructured":"EAU (2026) Guidelines. Edn. presented at the EAU Annual Congress London 2026 ISBN 978-94-92671-19\u20116.","ISBN":"https:\/\/id.crossref.org\/isbn\/9789492671196"},{"key":"2886_CR10","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","volume":"23","author":"CA Bellera","year":"2012","unstructured":"Bellera\u00a0CA, Rainfray\u00a0M, Mathoulin-Pelissier\u00a0S et\u00a0al (2012) Screening older cancer patients: first evaluation of the G\u20118 geriatric screening tool. Facts Views Vis Obgyn 23:2166\u20132172. https:\/\/doi.org\/10.1093\/annonc\/mdr587","journal-title":"Ann Oncol"},{"key":"2886_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115060","volume":"9","author":"P Soubeyran","year":"2014","unstructured":"Soubeyran\u00a0P, Bellera\u00a0C, Goyard\u00a0J et\u00a0al (2014) Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. PLoS One 9:e115060. https:\/\/doi.org\/10.1371\/journal.pone.0115060","journal-title":"PLoS One"},{"key":"2886_CR12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1046\/j.1532-5415.2003.51465.x","volume":"51","author":"S Borson","year":"2003","unstructured":"Borson\u00a0S, Scanlan\u00a0JM, Chen\u00a0P et\u00a0al (2003) The Mini-Cog as a screen for dementia: validation in a population-based sample. J\u00a0Am Geriatr Soc 51:1451\u20131454. https:\/\/doi.org\/10.1046\/j.1532-5415.2003.51465.x","journal-title":"J Am Geriatr Soc"},{"key":"2886_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006211.pub3","volume":"9","author":"G Ellis","year":"2017","unstructured":"Ellis\u00a0G, Gardner\u00a0M, Tsiachristas\u00a0A et\u00a0al (2017) Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev 9:CD006211. https:\/\/doi.org\/10.1002\/14651858.CD006211.pub3","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02886-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02886-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02886-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T11:09:50Z","timestamp":1791371390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02886-5"}},"subtitle":["Wie entscheiden wir altersgerecht beim Prostatakarzinom?","How do we decide on prostate cancer treatment in an age-appropriate way?"],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2886"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02886-5","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"30 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.\u00a0Fiebig: Bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Merck Healthcare Germany GmbH. Finanzielle Zuwendung f\u00fcr Forschungsvorhaben: Deutsche Forschungsgemeinschaft (DFG). A.\u00a0Manseck: Berater- bzw. Gutachtert\u00e4tigkeiten: Gerichtsgutachter; Gutachter Landes\u00e4rztekammer. Mitarbeit in einem wissenschaftlichen Beirat (\u201eadvisory board\u201c): F\u00f6rderverein zur Unterst\u00fctzung Krebskranker in der Region Ingolstadt e.\u202fV. Bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Urologie OnLine-Veranstalter: DGU; UroWorxx, Veranstalter: Christine Gerner; Boston Scientific Medizintechnik GmbH. Autoren-\/oder Koautorenschaft:\n                      \n                      . Indirekte Interessen \u2013\u00a0Mitgliedschaften: Generalsekret\u00e4r der bayerischen Urologenvereinigung; Schriftf\u00fchrer im Arbeitskreis Geriatrische Urologie der Deutschen Gesellschaft f\u00fcr Urologie; Schriftf\u00fchrer und Schatzmeister im Arbeitskreis Laparoskopie und roboterassistierte Chirurgie der Deutschen Gesellschaft f\u00fcr Urologie; Fachexperte Fa. OnkoZert; Mitglied im Ausschuss Zertifikatserteilung der Fa. OnkoZert; Mitglied der Zertifizierungskommission der Deutschen Krebsgesellschaft: Kommission Prostatakrebszentren\/Peniskarzinom (PZ); Mitglied der Zertifizierungskommission der Deutschen Krebsgesellschaft: Modul Harnblasenkarzinomzentren (MB); Mitglied der Zertifizierungskommission der Deutschen Krebsgesellschaft: Modul Nierenzellkarzinomzentren (MN). J.\u00a0Stein: Berater- bzw. Gutachtert\u00e4tigkeiten: Gutachter f\u00fcr Schlichtungsstellen \u00c4KN und \u00c4KHH; Fa. Bayer, AAA\/Novartis. Bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Fa. Medac, Fa. Lilly. Finanzielle Zuwendung f\u00fcr Forschungsvorhaben: Firmen: Astellas, Boston Scientific, Dr. Pfleger, Medtronic, Medac, Sanofi, Lilly, Jenapharm, AMS, Janssen, Pfizer, Takeda, MSD, Gr\u00fcnenthal, AAA\/Novartis. Besitz von Gesch\u00e4ftsanteilen, Aktien, Fonds mit Beteiligung von Unternehmen der Gesundheitswissenschaft: Bristol-Myers Squibb. A.\u00a0Piotrowski: Mitarbeit in einem wissenschaftlichen Beirat (\u201eadvisory board\u201c): Firma Bayer. Finanzielle Zuwendung f\u00fcr Forschungsvorhaben: Firma Pfleger. M.\u00a0Umbehr: Indirekte Interessen\u00a0\u2013 Mitgliedschaften: Schweizerische Gesellschaft f\u00fcr Urologie SGU; Deutsche Gesellschaft f\u00fcr Urologie DGU. M.\u00a0Butea-Bocu: Berater- bzw. Gutachtert\u00e4tigkeiten: Apogepha. Bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Apogepha, Astellas, MSD, Pfizer, Takeda. Finanzielle Zuwendung f\u00fcr Forschungsvorhaben: Intuitive. Indirekte Interessen \u2013\u00a0Mitgliedschaften: DGU, NRWGU, EAU. A.\u00a0Wiedemann: Berater- bzw. Gutachtert\u00e4tigkeiten: Acticore; Astellas; Bayer Pharma; Dr. Pfleger; Merck; MIP Arzneimittel; Novartis. Mitarbeit in einem wissenschaftlichen Beirat (\u201eadvisory board\u201c): Dr. Pfleger; Pfizer; MIP Arzneimittel; Bayer; Novartis. Bezahlte Vortrags-\/oder Schulungst\u00e4tigkeit: Allergan; AMS Deutschland; Aristo; Astellas Pharma; Bayer Pharma; Besins Deutschland; Berlin-Chemie; Das Fortbildungskolleg; Jansen; Lilly Deutschland; Meda; Merck; MIP Arzneimittel; Novartis; Dr. Pfleger; Pierre Fabre; Pfizer Pharma. Finanzielle Zuwendung f\u00fcr Forschungsvorhaben: AMS Deutschland; Boston Scientific; Dr. Pfleger; Paul-Kuth-Stiftung der Deutschen Bank. Indirekte Interessen\u00a0\u2013 Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Urologie (aktuell Leitung Arbeitskreis geriatrische Urologie); Deutsche Gesellschaft f\u00fcr Geriatrie (aktuell Leitung Arbeitsgruppe Harinkontinenz); NRW-Gesellschaft f\u00fcr Urologie (gew\u00e4hlt zum Kongresspr\u00e4sidenten 2025); Deutsche Kontinenzgesellschaft (aktuell 1.\u00a0Vorsitzender); Institut f\u00fcr Geriatrische Pharmazie und interdisziplin\u00e4re Geriatrie e.\u202fV. M.\u00a0Fr\u00f6hner gibt an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}